New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term ...
Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
Health and Me on MSN2d
Yearly Jab For HIV Protection Is Now Almost HereA yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...
A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...
Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.
"Once-yearly intramuscular lenacapavir for HIV PrEP has the potential to improve PrEP uptake and persistence and thus improve the scalability and public health impact of PrEP in populations who ...
HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results